Cytos Biotechnology Ltd of Switzerland said that top-line data from a Phase 2b clinical study of its lead product for allergic asthma should be available during the second quarter of 2014. The trial is taking place in eight countries. ---Subscribe to MedNous to access this article--- Company News Clinical Research